Free Trial
NASDAQ:IMNM

Immunome (IMNM) Stock Price, News & Analysis

Immunome logo
$8.77 -0.16 (-1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$9.00 +0.23 (+2.65%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Immunome Stock (NASDAQ:IMNM)

Key Stats

Today's Range
$8.75
$9.16
50-Day Range
$8.73
$11.83
52-Week Range
$8.39
$26.70
Volume
452,853 shs
Average Volume
893,254 shs
Market Capitalization
$699.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.17
Consensus Rating
Buy

Company Overview

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Remove Ads

Immunome Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
39th Percentile Overall Score

IMNM MarketRank™: 

Immunome scored higher than 39% of companies evaluated by MarketBeat, and ranked 769th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Immunome has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Immunome has only been the subject of 2 research reports in the past 90 days.

  • Read more about Immunome's stock forecast and price target.
  • Earnings Growth

    Earnings for Immunome are expected to decrease in the coming year, from ($2.21) to ($3.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Immunome is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Immunome is -1.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Immunome has a P/B Ratio of 3.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Immunome's valuation and earnings.
  • Percentage of Shares Shorted

    13.35% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently decreased by 0.53%, indicating that investor sentiment is improving.
  • Dividend Yield

    Immunome does not currently pay a dividend.

  • Dividend Growth

    Immunome does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.35% of the float of Immunome has been sold short.
  • Short Interest Ratio / Days to Cover

    Immunome has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Immunome has recently decreased by 0.53%, indicating that investor sentiment is improving.
  • News Sentiment

    Immunome has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 17 news articles for Immunome this week, compared to 4 articles on an average week.
  • MarketBeat Follows

    12 people have added Immunome to their MarketBeat watchlist in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Immunome insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,162,500.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 8.60% of the stock of Immunome is held by insiders.

  • Percentage Held by Institutions

    44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Immunome's insider trading history.
Receive IMNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter.

IMNM Stock News Headlines

An AI warning from a Wall Street legend
AI is creeping into every aspect of our daily lives… According to billion-dollar fund manager Louis Navellier, it's never been more important to AI-proof your wealth. He lays out three simple steps to take ASAP in his new video.
Immunome initiated with an Outperform at LifeSci Capital
Immunome (NASDAQ:IMNM) Earns "Outperform" Rating from Wedbush
Immunome doses first patient in IM-1021 trial
See More Headlines

IMNM Stock Analysis - Frequently Asked Questions

Immunome's stock was trading at $10.62 at the beginning of 2025. Since then, IMNM shares have decreased by 16.6% and is now trading at $8.8620.
View the best growth stocks for 2025 here
.

Immunome, Inc. (NASDAQ:IMNM) released its earnings results on Monday, November, 15th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $0.14. Immunome had a negative trailing twelve-month return on equity of 48.63% and a negative net margin of 3,014.59%.

Immunome (IMNM) raised $30 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 2,500,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Chardan acted as the underwriters for the IPO.

Immunome's top institutional shareholders include T. Rowe Price Investment Management Inc. (6.89%), Redmile Group LLC (6.05%), Enavate Sciences GP LLC (4.36%) and Janus Henderson Group PLC (4.33%). Insiders that own company stock include Max Rosett, Bruce Turner, Philip Tsai, Jack Higgins and Robert Lechleider.
View institutional ownership trends
.

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/15/2021
Today
3/14/2025
Next Earnings (Estimated)
3/27/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:IMNM
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.17
High Stock Price Target
$35.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+204.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-106,810,000.00
Net Margins
-3,014.59%
Pretax Margin
-3,014.59%

Debt

Sales & Book Value

Annual Sales
$10.13 million
Price / Cash Flow
N/A
Book Value
$2.77 per share
Price / Book
3.22

Miscellaneous

Free Float
72,916,000
Market Cap
$712.41 million
Optionable
Optionable
Beta
1.93
7 Top Nuclear Stocks To Buy Now Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:IMNM) was last updated on 3/14/2025 by MarketBeat.com Staff
From Our Partners